The regenerative medicine market was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030. Regenerative medicines are used to repair, replace, and regenerate tissues and organs affected by injury, disease, or natural aging process. These medicines restore the functionality of cells & tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Stem cells are capable of proliferation and differentiation, which increase their importance in this field.
Increase in prevalence of musculoskeltal diseases, oncological disorders, and dental disorders is the major factor that contributes in the growth of the regenerative medicine market. Moreover, other factors that fuel the market growth include, increase in adoption of regenerative medicine products and technological advancement in stem cell-based therapies that have revolutionized the perspective research towards regenerative medicine. In addition, many companies are increasing their market presence, thereby expanding their business across new markets. For instance, in July 2021, Pharming Group N.V and Orchard collaborated for the development of commercialized OTL 105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Such factors have led to the growth of the regenerative medicine market.
Emergence of stem cell technology, untapped potential of nanotechnology, increase in prevalence of chronic diseases & trauma emergencies, advancement in monitoring devices and surgical technologies, rise in incidence of degenerative diseases, and shortage of organs for transplantation are major factors that drive the growth of the regenerative medicine market. Increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth in the coming years. Developing nations are focused on technological advancements, which is expected to boost the market growth, globally. However, stringent government regulations, operational inefficiency, and high cost of treatment of regenerative medicines are estimated to hamper the growth of the regenerative medicine market.
Conversely, development of cost-effective therapeutics through large-scale production and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market. People, nowadays are becoming more health conscious, which compels them to maintain their health condition. Thus increasing the demand for regenerative medicine. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the regenerative medicine market.
The regenerative medicine market is segmented on the basis of product type, material, application, and geography. On the basis of product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic.
On the basis of material, the market is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic.
On the basis of application, the market is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. On the basis of region, the market is analyzed across four regions, such as North America, Europe, Asia-Pacific, and LAMEA.
By material, the biologically derived material was the dominant segment in 2020, and is estimated to maintain this trend during the forecast period. The demand for genetically engineered material has increased due to their unique, such as promotion of cellular interactions, rise in proliferation, and differentiation of cells that facilitate self-assembly into directionally organized structures, and control the manipulation of cellular behavior.
By application the musculoskeletal application segment accounted for the largest share in 2020, whereas cardiovascular is expected to be the fastest-growing segment, registering a CAGR of 23.8% during the forecast period.
The use of regenerative medicine is highest in North America, particularly in the U.S., owing to increase in prevalence of chronic disorders, rise in demand for artificial organs due to organ failure, and presence of highly sophisticated healthcare infrastructure. Although the use of regenerative medicine in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to the presence of high unmet medical needs and constant improvement in the healthcare infrastructure to treat chronic disorders. In addition, countries such as China, India, Australia, and Japan contribute to the market growth owing to their large population and rise in demand for tissue-engineered and regenerative medicine products. These countries have varying demographics and cultural conditions, which highly influence their respective markets.
The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc.
Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.
Increase in prevalence of musculoskeltal diseases, oncological disorders, and dental disorders is the major factor that contributes in the growth of the regenerative medicine market. Moreover, other factors that fuel the market growth include, increase in adoption of regenerative medicine products and technological advancement in stem cell-based therapies that have revolutionized the perspective research towards regenerative medicine. In addition, many companies are increasing their market presence, thereby expanding their business across new markets. For instance, in July 2021, Pharming Group N.V and Orchard collaborated for the development of commercialized OTL 105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Such factors have led to the growth of the regenerative medicine market.
Emergence of stem cell technology, untapped potential of nanotechnology, increase in prevalence of chronic diseases & trauma emergencies, advancement in monitoring devices and surgical technologies, rise in incidence of degenerative diseases, and shortage of organs for transplantation are major factors that drive the growth of the regenerative medicine market. Increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth in the coming years. Developing nations are focused on technological advancements, which is expected to boost the market growth, globally. However, stringent government regulations, operational inefficiency, and high cost of treatment of regenerative medicines are estimated to hamper the growth of the regenerative medicine market.
Conversely, development of cost-effective therapeutics through large-scale production and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market. People, nowadays are becoming more health conscious, which compels them to maintain their health condition. Thus increasing the demand for regenerative medicine. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the regenerative medicine market.
The regenerative medicine market is segmented on the basis of product type, material, application, and geography. On the basis of product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic.
On the basis of material, the market is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic.
On the basis of application, the market is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. On the basis of region, the market is analyzed across four regions, such as North America, Europe, Asia-Pacific, and LAMEA.
By material, the biologically derived material was the dominant segment in 2020, and is estimated to maintain this trend during the forecast period. The demand for genetically engineered material has increased due to their unique, such as promotion of cellular interactions, rise in proliferation, and differentiation of cells that facilitate self-assembly into directionally organized structures, and control the manipulation of cellular behavior.
By application the musculoskeletal application segment accounted for the largest share in 2020, whereas cardiovascular is expected to be the fastest-growing segment, registering a CAGR of 23.8% during the forecast period.
The use of regenerative medicine is highest in North America, particularly in the U.S., owing to increase in prevalence of chronic disorders, rise in demand for artificial organs due to organ failure, and presence of highly sophisticated healthcare infrastructure. Although the use of regenerative medicine in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to the presence of high unmet medical needs and constant improvement in the healthcare infrastructure to treat chronic disorders. In addition, countries such as China, India, Australia, and Japan contribute to the market growth owing to their large population and rise in demand for tissue-engineered and regenerative medicine products. These countries have varying demographics and cultural conditions, which highly influence their respective markets.
The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc.
Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global albumin market to identify the prevailing opportunities
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies
- Comprehensive analysis of factors that drive and restrict the market growth is provided
- Region- & country-wise analysis is provided to understand the market trends and dynamics
KEY MARKET SEGMENTS
By Product Type
- Cell Therapy
- Gene Therapy
- Tissue Engineering
- Small Molecule & Biologic
By Material
- Synthetic Material
- Biodegradable Synthetic Polymer
- Scaffold
- Artificial Vascular Graft Material
- Hydrogel Material
- Biologically Derived Material
- Collagen
- Xenogeneic Material
- Genetically Engineered Material
- Deoxyribonucleic Acid Transfection Vector
- Genetically Manipulated Cell
- Three-Dimensional Polymer Technology
- Pharmaceutical
- Small Molecule
- Biologic
By Application
- Cardiovascular
- Oncology
- Dermatology
- Musculoskeletal
- Wound Healing
- Ophthalmology
- Neurology
- Others
By End User
- Hospitals
- Ambulatory Surgical Center
- Others
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- 3 M
- Athersys Inc
- Cryo Life Inc
- Integra Life Sciences
- Isto Biologics
- Medtronic Plc
- Organogenesis
- Stryker Corporation
- US Stem Cell Inc
- Zimmer Biomet Holdings Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Regenerative Medicine Market, by Product Type
Chapter 5: Regenerative Medicine Market, by Material
Chapter 6: Regenerative Medicine Market, by Application
Chapter 7: Regenerative Medicine Market, by Region
Chapter 8: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, “Regenerative Medicine Market by Type, Material, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030,” the regenerative medicine market size was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030.Regenerative medicine is a process of replacing human cells, tissues or organs to restore or establish normal function. It is field that brings together experts in biology, chemistry, genetics and medicine. This is a promising field which working to restore structure and function of damaged tissues and organs. It includes cell therapy involves the use of cellular materials such as stem cells, autologous cells, xenogeneic cells, and others, for the therapeutic treatment of patients. Cell therapy is used to replace damaged cells, deliver therapies to target tissues/organs, stimulate self-healing, and various other applications in regenerative medicine.
The major factors boosting the regenerative medicine market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, increase in incidence of degenerative diseases and shortage of organs for transplantation are expected to boost the growth of the market. The prominent potential of regenerative medicine to replace, repair, and regenerate damaged tissues and organs has fueled the market growth. In addition, technological advancements in regenerative medicine production and advancement in the stem cell therapy procedures propel the growth of the market. Rise in prevalence of musculoskeletal diseases and increase in dermatological treatments propel the growth of the market. Moreover, utilization of nanomaterial’s in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market.
However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are key factors that hinder the market growth. Furthermore, advancements in stem cell technology and increase in R&D activities in the emerging economies are expected to fuel the market growth during the forecast period. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which help in the expansion of the global market.
Moreover, rise in development of pharmaceutical and medical device industries and improvement in healthcare spending are anticipated to drive the growth of the regenerative medicine market. In addition, increase in demand for regenerative medicine led to development of innovative technologies in the healthcare sector, thereby propelling growth of the market.
Moreover, initiatives taken by governments for development of advanced stem cell therapies and development of the healthcare sector for manufacturing of regenerative medicine are the key factors that boost growth of the market. Furthermore, surge in geriatric population, who are more vulnerable to chronic disease, propels the market growth.
The regenerative medicine market is segmented on the basis of type, material, application, end user, and region. On the basis of type, the market is divided into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. The XXX segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of cancer cases and advancements in R&D activities in pharmaceutical & medical device industries.
By material, the market is fragmented into synthetic material, biologically derived material, genetically engineered material, and pharmaceuticals.
By application, the market is classified into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. The xxx segment acquired top position in the market in 2020, and this trend is expected to continue during the forecast period, owing to large number of regenerative medicine products offered by key players and increase in demand for cell therapies for treatment of various disorders.
By end user, the market is classified into hospitals & clinics, ambulatory surgical centers, and others. The XXX segment led the market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in technology in the healthcare sector.
North America accounted for a majority of the global regenerative medicine market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products, increase in number of approvals for regenerative medicine products, presence of key players, and development in technology for healthcare in the region. Asia-Pacific is anticipated to witness lucrative growth, due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.
Key Findings Of The Study
- By type, the XXX segment was the highest contributor to the market in 2020
- On the basis of application type, the XXX segment dominated the regenerative medicine market in 2020, and is expected to continue this trend during the forecast period
- Depending on end user, the XXX segment was the highest contributor to the market in 2020
- Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Stryker Corporation
- Zimmer Biomet Holdings, Inc.
- Medtronic Plc.
- Athersys, Inc.
- U.S. Stem Cell, Inc. (Bioheart, Inc.)
- Organogenesis, Inc. (Advanced Biohealing)
- Integra Lifesciences Holdings Corporation
- Acelity Holdings, Inc.
- Isto Biologics (Isto Biologics Medical Systems, Inc.)
- CryoLife, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 257 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 10107.32 million |
| Forecasted Market Value ( USD | $ 83196.72 million |
| Compound Annual Growth Rate | 23.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
